Doença hepática relacionada à fibrose cística: patogênese, diagnóstico e abordagens terapêuticas

##plugins.themes.bootstrap3.article.main##

Amanda Lira Gonçalves de Medeiros
Nathália Winttr Cariello
Erik Rogai de Souza
Maraiza Carneiro
Rafaela de Almeida Carvalho
Sabrina Possani Tabile
Gabriel Destro Miranda
Vitória Viviane Ciceri Buffon
Vitória Costa Souza
Neidejany de Assunção do Sacramento

Resumo

Objetivo: Examinar a prevalência, os mecanismos patofisiológicos e as abordagens de manejo da doença hepática em pacientes com fibrose cística, com foco na identificação de fatores que influenciam a progressão da doença e na eficácia das intervenções terapêuticas atuais. Métodos: Trata-se de um estudo de revisão bibliográfica integrativa, utilizando o PubMed como base de dados. Os termos de pesquisa incluíram “fibrose cística”, “doença hepática” e seus derivados. No total, foram selecionados e analisados 11 artigos. Resultados: A prevalência da doença hepática em pacientes com fibrose cística mostrou-se expressiva, sendo identificada como a principal causa de mortalidade não pulmonar. No que diz respeito às opções terapêuticas, observou-se que, embora não sejam preventivas, as terapias com moduladores da proteína CFTR diminuem de forma significativa as complicações associadas à doença hepática, como a cirrose. Considerações finais: Este estudo contribui para uma compreensão mais aprofundada dos mecanismos da doença, bem como para o aprimoramento de estratégias de tratamento, diagnóstico e prognóstico da doença hepática em pacientes com fibrose cística. No entanto, destaca-se a necessidade de pesquisas futuras e aprofundadas, de forma proporcional à complexidade do tema abordado.

##plugins.themes.bootstrap3.article.details##

Como Citar
MedeirosA. L. G. de, CarielloN. W., SouzaE. R. de, CarneiroM., CarvalhoR. de A., TabileS. P., MirandaG. D., BuffonV. V. C., SouzaV. C., & SacramentoN. de A. do. (2025). Doença hepática relacionada à fibrose cística: patogênese, diagnóstico e abordagens terapêuticas. Revista Eletrônica Acervo Saúde, 25, e18996. https://doi.org/10.25248/reas.e18996.2025
Seção
Revisão Bibliográfica

Referências

1. ANTON-PADURARU DT, et al. Diagnosis, Management, and Prognosis of Cystic. Fibrosis-Related Liver Disease in Children. Diagnostics, 2024; 14(5): e-538.

2. BAKER RD, BAKER SS. Cystic Fibrosis-related Liver Disease: The Next Challenge. Journal of Pediatric Gastroenterology and Nutrition, 2020; 71(4): 421-422.

3. HERMIE L, et al. Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results. Diagnostic and Interventional Radiology, 2024; 30(1): 55-64.

4. KARLAS T, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PlosOne; 2012; 7: e42139.

5. MARTONOSI AR, et al. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Frontiers in Medicine, 2021; (8): 1-11, e-598382.

6. MARTONOSI ÁR, et al. Non-invasive diagnostic tests in cystic fibrosis-related liver disease: a diagnostic test accuracy network meta-analysis. Frontiers in Medicine, 2021; 8: 598382.

7. MIELUS M, et al. Improving nutrition in cystic fibrosis: A systematic literature review. Nutrition. 2022 ;102:111725.

8. MÖLLER K, et al. Comments and illustrations of the WFUMB CEUS liver guidelines: Cystic fibrosis associated liver disease. Medical ultrasonography, 2023; 1-7.

9. RAMSEY ML, et al. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World Journal of Hepatology, 2022; 14(2): 411-419.

10. SAKHUJA S, et al. Risk factors for more rapid progression of severe liver fibrosis in children with cystic fiibrosis-related liver disease: A multi-center study validated by liver biopsy. Liver International, 2023; 43(6): 1277–1286.

11. SANKARARAMAN S, FREEMAN AJ. Early detection of hepatobiliary involvement in cystic fibrosis: Biomarkers, radiologic methods, and genetic influences. Pediatric Pulmonology, 2024; 59: S107-S114.

12. SCHWARZENBERG SJ, et al. Health-related quality of life in a prospective study of ultrasound to detect cystic fibrosis-related liver disease in children. Journal of Pedriatic Gastroenterology and Nutrition, 2022; 75(5): 635–642.

13. SCOTT J, et al. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Alimentary Pharmacology & Therapeutics, 2022; 55(4): 389-400

14. SCOTT JA, et al. Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools. Heliyon, 2023; 9(11): e21861.

15. SHERWOOD JS, et al. Cystic fibrosis related liver disease and endocrine considerations. Journal of Clinical & Translational Endocrinology, 2022; 27: 1-6, e100283.

16. SINANI SA, et al. Cystic Fibrosis Liver Disease: Know More. Oman Medical Journal, 2019; 34(6): 482-489.
17. SINGH H, et al. Cystic Fibrosis-related Liver Disease is Associated With Increased Disease Burden and Endocrine Comorbidities. Journal of Pediatric Gastroenterology and Nutrition, 2020; 70(6): 796-800.

18. STAUFER K. Current treatment options for cystic fibrosis-related liver disease. International journal of molecular sciences, 2020; 21(22): 8586.

19. THAVAMANI A, et al. Cystic fibrosis‐related liver disease is an independent risk factor for mortality and increased health care resource utilization in hospitalized pediatric patients with cystic fibrosis. Pediatric Pulmonology, 2022; 57(7): 1717-1725.

20. TICONA JH, et al. Future Comorbidities in an Aging Cystic Fibrosis Population. Life, 2023; 13(6): 1-11, e1305.